COVID-19 and rheumatoid arthritis

Area of Science:

• Rheumatology
• Infectious Diseases
• Public Health

Background:

• The COVID-19 pandemic has significantly impacted global health, causing widespread morbidity and mortality.
• Patients with rheumatoid arthritis (RA) experience distinct challenges, including heightened infection risks and disruptions to care.
• These challenges encompass concerns about drug availability, limited healthcare access, social isolation, and mental well-being.

Purpose of the Study:

• To review the multifaceted effects of the COVID-19 pandemic on individuals living with rheumatoid arthritis.
• To examine the unique challenges faced by RA patients during the pandemic.
• To synthesize current understanding of COVID-19's impact on RA management and patient outcomes.

Main Methods:

• This study is a review of existing literature and data.
• It synthesizes findings on risk factors, treatment implications, and patient experiences during the pandemic.
• The review examines impacts on disease activity, access to care, and mental health.

Main Results:

• Risk factors for severe COVID-19 in RA patients include advanced age and comorbidities, mirroring the general population.
• Glucocorticoids, unlike other disease-modifying antirheumatic drugs (DMARDs), are associated with an increased risk of severe COVID-19 outcomes.
• RA patients reported significant disruptions, including altered access to care, increased telemedicine use, drug shortages, anxiety, and social isolation, potentially leading to disease flares.

Conclusions:

• Glucocorticoids are linked to a higher risk of severe COVID-19 outcomes in RA patients, whereas other DMARDs do not show this association.
• Further research is required to elucidate the specific impact of various DMARDs on COVID-19 outcomes in RA.
• Investigating the broader implications of the pandemic on RA disease activity and optimizing telemedicine strategies are crucial for future patient care.